Harvard Bioscience, Inc. (HBIO)
NASDAQ: HBIO · Real-Time Price · USD
6.66
-0.01 (-0.22%)
Aug 14, 2026, 4:00 PM EDT - Market closed
Harvard Bioscience Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 87.81 | 86.55 | 94.14 | 112.25 | 113.34 | 118.9 | |
Revenue Growth | -1.06% | -8.06% | -16.14% | -0.96% | -4.68% | 16.46% |
Cost of Revenue | 36.74 | 36.64 | 39.33 | 45.86 | 51.05 | 51.25 |
Gross Profit | 51.07 | 49.91 | 54.81 | 66.39 | 62.29 | 67.65 |
Selling, General & Admin | 36.66 | 35.56 | 43.52 | 46.61 | 49.03 | 47.32 |
Research & Development | 9.09 | 8.83 | 10.41 | 11.76 | 12.33 | 10.8 |
Amortization of Goodwill & Intangibles | 3.35 | 4.03 | 5.26 | 5.53 | 6.12 | 5.84 |
Other Operating Expenses | - | - | 0.35 | - | - | - |
Operating Expenses | 49.1 | 48.41 | 59.53 | 63.9 | 67.48 | 63.96 |
Operating Income | 1.97 | 1.5 | -4.72 | 2.5 | -5.19 | 3.69 |
Interest Expense | -6.5 | -4.92 | -3.54 | -3.59 | -2.55 | -1.54 |
Currency Exchange Gain (Loss) | 0.63 | - | - | - | - | - |
Other Non Operating Income (Expenses) | -5.82 | -5.29 | -0.51 | -0.44 | 0.72 | -1.02 |
EBT Excluding Unusual Items | -9.72 | -8.71 | -8.77 | -1.53 | -7.02 | 1.14 |
Merger & Restructuring Charges | -0.62 | -0.19 | -0.84 | -0.39 | -2.39 | -1.28 |
Impairment of Goodwill | - | -47.95 | - | - | - | - |
Gain (Loss) on Sale of Investments | - | - | -1.59 | -0.63 | - | - |
Legal Settlements | - | - | - | - | 0.23 | - |
Other Unusual Items | -0.2 | -0.54 | -0.47 | - | - | - |
Pretax Income | -10.54 | -57.39 | -11.67 | -2.56 | -9.18 | -0.14 |
Income Tax Expense | -0.13 | -0.69 | 0.74 | 0.86 | 0.34 | 0.15 |
Earnings From Continuing Operations | -10.41 | -56.7 | -12.41 | -3.42 | -9.52 | -0.29 |
Net Income | -10.41 | -56.7 | -12.41 | -3.42 | -9.52 | -0.29 |
Net Income to Common | -10.41 | -56.7 | -12.41 | -3.42 | -9.52 | -0.29 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 4 | 4 | 4 | 4 | 4 | 4 |
Shares Outstanding (Diluted) | 4 | 4 | 4 | 4 | 4 | 4 |
Shares Change | 1.81% | 1.96% | 2.64% | 2.43% | 2.65% | 4.41% |
EPS (Basic) | -2.33 | -12.77 | -2.85 | -0.81 | -2.30 | -0.07 |
EPS (Diluted) | -2.35 | -12.80 | -2.85 | -0.81 | -2.30 | -0.10 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -1.12 | 5.47 | -1.2 | 12.24 | -0.44 | 0.07 |
Free Cash Flow Per Share | -0.25 | 1.23 | -0.28 | 2.88 | -0.11 | 0.02 |
Gross Margin | 58.16% | 57.67% | 58.22% | 59.15% | 54.96% | 56.90% |
Operating Margin | 2.25% | 1.73% | -5.01% | 2.22% | -4.58% | 3.10% |
Profit Margin | -11.86% | -65.51% | -13.18% | -3.04% | -8.40% | -0.24% |
Free Cash Flow Margin | -1.27% | 6.32% | -1.28% | 10.90% | -0.39% | 0.06% |
EBITDA | 7.37 | 7.44 | 2.44 | 9.49 | 2.38 | 11.31 |
EBITDA Margin | 8.39% | 8.60% | 2.59% | 8.46% | 2.10% | 9.51% |
D&A For EBITDA | 5.4 | 5.95 | 7.16 | 7 | 7.58 | 7.62 |
EBIT | 1.97 | 1.5 | -4.72 | 2.5 | -5.19 | 3.69 |
EBIT Margin | 2.25% | 1.73% | -5.01% | 2.22% | -4.58% | 3.10% |